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Introduction: At tamoxifen standard dosing, ∼20% of breast cancer patients do
not reach proposed target endoxifen concentrations >5.97 ng/mL. Thus, better
understanding the large interindividual variability in tamoxifen pharmacokinetics (PK)
is crucial. By applying non-linear mixed-effects (NLME) modeling to a pooled ‘real-
world’ clinical PK database, we aimed to (i) dissect several levels of variability and
identify factors predictive for endoxifen exposure and (ii) assess different tamoxifen
dosing strategies for their potential to increase the number of patients reaching target
endoxifen concentrations.
Methods: Tamoxifen and endoxifen concentrations with genetic and demographic
data of 468 breast cancer patients from six reported studies were used to develop a
NLME parent-metabolite PK model. Different levels of variability on model parameters
or measurements were investigated and the impact of covariates thereupon explored.
The model was subsequently applied in a simulation-based comparison of three dosing
strategies with increasing degree of dose individualization for a large virtual breast
cancer population. Interindividual variability of endoxifen concentrations and the fraction
of patients at risk for not reaching target concentrations were assessed for each
dosing strategy.
Results and Conclusions: The integrated NLME model enabled to differentiate
and quantify four levels of variability (interstudy, interindividual, interoccasion, and
intraindividual). Strong influential factors, i.e., CYP2D6 activity score, drug–drug
interactions with CYP3A and CYP2D6 inducers/inhibitors and age, were reliably
identified, reducing interoccasion variability to <20% CV. Yet, unexplained interindividual
variability in endoxifen formation remained large (47.2% CV). Hence, therapeutic drug
monitoring seems promising for achieving endoxifen target concentrations. Three
tamoxifen dosing strategies [standard dosing (20 mg QD), CYP2D6-guided dosing (20,
40, and 60 mg QD) and individual model-informed precision dosing (MIPD)] using three
therapeutic drug monitoring samples (5–120 mg QD) were compared, leveraging the
model. The proportion of patients at risk for not reaching target concentrations was
22.2% in standard dosing, 16.0% in CYP2D6-guided dosing and 7.19% in MIPD.
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While in CYP2D6-guided- and standard dosing interindividual variability in endoxifen
concentrations was high (64.0% CV and 68.1% CV, respectively), it was considerably
reduced in MIPD (24.0% CV). Hence, MIPD demonstrated to be the most promising
strategy for achieving target endoxifen concentrations.
Keywords: tamoxifen, modeling, simulation, pharmacokinetics, individualized dosing, model-informed precision
dosing
INTRODUCTION
Even after 40 years since approval, tamoxifen remains one of
the most important and frequently used oral anticancer drugs in
the treatment of all stages of estrogen receptor-positive (ER+)
breast cancer. Despite the therapeutic success in many breast
cancer patients, unfortunately some patients do not respond
or suffer from loss of response (Davies et al., 2013). High
interindividual variability is observed in the PK of tamoxifen –
and especially its active metabolite endoxifen – after standard
doses of 20 mg tamoxifen once daily (QD). This variability has
been partly attributed to genetic variations in the metabolizing
enzyme CYP2D6 (Schroth et al., 2007; Mürdter et al., 2011;
Ratain et al., 2013; Ter Heine et al., 2014). The variable endoxifen
exposure is likely to contribute to the observed differences
in clinical outcome and yet the ‘one-dose-fits-all’ treatment
strategy is common practice. In the last decade, several clinical
studies on tamoxifen treatment individualization have shown
controversial results (Goetz et al., 2005; Barginear et al., 2011;
Irvin et al., 2011; Regan et al., 2012; Martinez et al., 2014; Dezentjé
et al., 2015; Welzen et al., 2015; Hertz et al., 2016; DeCensi
et al., 2019; Khalaj et al., 2019) and caused intensive debates
(Hoskins et al., 2009; Lash et al., 2009; Brauch et al., 2013;
Binkhorst et al., 2015b).
This inevitably introduced uncertainty rather than solutions,
by means of clear and useful guidance on how to make
tamoxifen dosing decisions in clinical practice (Goetz et al.,
2018). However, there seems to be considerable consensus
that endoxifen, a secondary metabolite of tamoxifen, is an
important driver of tamoxifen efficacy – being 100-fold more
potent than its parent tamoxifen (Johnson et al., 2004; Kisanga
et al., 2004; Lim et al., 2005; Mürdter et al., 2011; Gjerde
et al., 2012). Two clinical studies have proposed a therapeutic
threshold concentration of endoxifen in plasma which has
been related to improved clinical outcome, i.e., a 26% reduced
risk of breast cancer recurrence, longer distant relapse-free
survival and reduced breast cancer-related death (Madlensky
et al., 2011; Saladores et al., 2015). Applying this threshold,
about 1 out of 5 patients will not reach therapeutic endoxifen
concentrations under tamoxifen standard dosing and are thus
at risk of treatment failure (Madlensky et al., 2011). Tamoxifen
is still frequently used in pre- and postmenopausal ER+ breast
cancer patients, and methods to achieve endoxifen plasma
concentrations within the therapeutic target in all patients are
of high interest.
Model-informed precision dosing (MIPD) aims to tailor doses
to patients’ needs, and is therefore a promising tool to increase
treatment success (Darwich et al., 2017). In this approach,
patient characteristics are combined with information about
drug pharmacokinetics (PK) and knowledge about exposure-
response relationships in a comprehensive model-informed dose
selection framework. While MIPD is increasingly applied in
other therapeutic areas, i.e., anti-infective therapy (Darwich et al.,
2017), it is virtually absent in oncology. Given the complex PK
of tamoxifen, i.e., long time to steady-state (up to 1 month for
tamoxifen, up to 3 months for endoxifen), extensive metabolism
involving several polymorphic enzymes and a high potential
for drug–drug interactions (DDIs), a model-informed approach
seems particularly suitable to capture influential factors and
quantify their impact on the PK of tamoxifen and endoxifen.
Prior to conducting a ‘real’ clinical study, it is useful to
circumvent the many limitations associated with a clinical trial
and first explore the impact of the proposed intervention using
a less time- and resource-consuming in silico approach. The
in silico approach further allows to study scenarios which would
be challenging and/or time consuming to observe in ‘real-
life,’ due to the rareness of subpopulations (i.e., CYP2D6 poor
metabolizer) or ethical concerns (investigating doses outside the
approved dose range).
Based on this status quo, the aim of this work was (i) to
enhance the quantitative understanding of the highly variable
pharmacokinetics and pharmacogenetics of tamoxifen and
its major active metabolite endoxifen and (ii) to investigate
intrinsic and extrinsic factors causing subtarget endoxifen
plasma concentrations in order (iii) to propose a possible
clinical trial design [i.e., how many therapeutic drug monitoring
(TDM) samples should be taken and when] to evaluate
the clinical benefit of model-informed precision dosing of
tamoxifen. To that end, first a large and modular ‘clinical
PK database’ for modeling & simulation (M&S) analyses of
tamoxifen and its metabolites was created by pooling six clinical
studies, enabling subsequent integrated data analyses utilizing
pharmacometric approaches. Secondly, a joint non-linear
mixed-effects pharmacokinetic (NLME-PK) model of tamoxifen
and endoxifen was developed and evaluated by integrating
information on clinical pharmacokinetics, pharmacogenetics
and CYP-mediated drug–drug interactions from the established
PK database. Thirdly, within the NLME-PK model, multiple
levels of random variability in the most relevant PK processes
were dissected, quantified and characterized to determine the
magnitude of ‘real-world’ variability and to detect sources of
PK variability (patient- and treatment-specific characteristics),
thereby identifying patients at risk of subtarget endoxifen
concentrations. Finally, the NLME-PK model was applied to
investigate and compare three different dosing strategies, namely
standard dosing, CYP2D6-adapted dosing and MIPD. Clinical
Frontiers in Pharmacology | www.frontiersin.org 2 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 3
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
trial simulations were used to demonstrate advantages and
disadvantages of the respective strategies and thus guide toward
a more appropriate, individualized treatment strategy.
MATERIALS AND METHODS
Clinical PK Database of Tamoxifen and
Endoxifen
A single ‘clinical PK database’ was generated by pooling
multiple clinical datasets from six reported clinical investigator-
initiated tamoxifen trials [hereinafter referred to as studies
1–6 (de Graan et al., 2011; Binkhorst et al., 2012, 2015a,
2016; Poppe et al., 2016; Neven et al., 2018)], all carried out
in line with the recommendations of the World Medical
Association’s Declaration of Helsinki and their study protocols
approved by the respective ethics committee. All patients
gave written informed consent prior to participation.
Each study contributed relevant clinical pharmacokinetic,
pharmacogenetic and demographic information representing
clinical routine, “real-world” data. ‘Real-world’ data refer
to data from non-randomized controlled trials, e.g., clinical
investigator-initiated trials and observational cohort studies,
which reflect a real-world scenario (Franklin et al., 2019).
The database assembled an extensive collection of plasma
concentration data of tamoxifen and its major metabolite
endoxifen (nPK observations = 3554) and a variety of patient
information from 468 breast cancer patients (Table 1). Due
to the original objectives of the single studies, respective
study designs, study population sizes and blood sampling
frequencies differed (Table 1). Inclusion and exclusion criteria,
analytical methods and treatment settings for each study are
provided in the Supplementary Material (see section “Extended
Information on the Six Clinical Tamoxifen Studies Featured in
the Clinical PK Database”).
Pharmacogenetics: CYP2D6 Genotype-to-Phenotype
Predictions
To derive a patient’s CYP2D6 phenotype, the available
genotype information, i.e., detected genetic polymorphisms
(single nucleotide polymorphisms, SNPs, and copy number
variants, CNVs), was translated via three steps: (1) From
the reported nucleotide variation (wild-type ‘wt’ or altered
nucleotide sequence ‘mut’) to a biallelic genotype, e.g., wt/mut:
∗1/∗41; (2) from the genotype to the activity score (AS), e.g.,
∗1/∗41 → 1.5; (3) From the AS to the ‘traditional’ CYP2D6
phenotype category, e.g., 1.5 → normal metabolizer, gNM.
The activity score assignment was performed based on the
Clinical Pharmacogenetics Implementation Consortium (CPIC)
guideline (Gaedigk et al., 2017; Goetz et al., 2018). The
CPIC is an international consortium of experts developing
evidence-based gene/drug clinical practice guidelines (CPIC,
2019) and therapeutic recommendations. Thus, each patient
in the PK database was assigned a CYP2D6 activity score
(seven AS categories from 0 to 3 in intervals of 0.5) and
a respective CYP2D6 phenotype [four categories: poor
(gPM, AS: 0), intermediate (gIM, AS: 0.5), normal (gNM,
AS:1-2), and ultrarapid (gUM, AS ≥ 2) metabolizer; see
Figure 1]. The prefix ‘g’ indicates the phenotype prediction
from genotype.
Non-linear Mixed-Effects PK Model
Approach to Dissect, Quantify and
Characterize Multiple Levels of Variability
For the purpose of better understanding the – unexplainable and
explainable – variability in tamoxifen and endoxifen exposure,
and to address questions concerning potential tamoxifen dose
optimization strategies, a joint parent-metabolite model focusing
on key covariate-parameter relationships was developed.
Structural Model Development
The structural submodel aimed to describe the general trend
in the observed data of both tamoxifen and its most active
metabolite endoxifen using a system of ordinary differential
equations. One-compartment as well as two-compartment
models for tamoxifen with first- or zero-order absorption with
or without lag-time and linear or non-linear clearance as well
as endoxifen formation were evaluated. The structural model
describing the observed tamoxifen and endoxifen concentrations
best was carried forward for the development of the statistical
submodel. PK parameters for tamoxifen and endoxifen were
simultaneously estimated.
Statistical Submodel Development
The statistical model aimed to incorporate four levels of
variability around the structural model. Thus, and due to
the nature of the database, a nested hierarchy of random-
effects components was set up comprising interstudy (ISV),
interindividual (IIV), interoccasion (IOV), and residual
unexplained variability (RUV) (see Supplementary Figure S1).
While ISV and IIV characterize random deviations between
different studies and patients, respectively, IOV describes the
random variability within an individual patient across different
occasions. The RUV captures the remaining variability across
all observations.
IIV was evaluated on all structural PK parameters and
implemented using exponential IIV models (Equation 1).
Resulting individual PK parameters were assumed to arise from
a log-normal distribution in which the ηik values are normally
distributed with mean zero and variance estimate ω 2k .
θik = θk · eηik ηik ∼ N (0,ω2k) (1)
with typical PK parameter θk and patient individual PK
parameter θikfor patient i = 1, . . . ,N and PK parameter
k = 1, . . . ,N.
While 27% of the patients had samples collected on one
occasion (study day, i.e., one dosing interval = 1 day) only, 73% of
patients in the PK database had samples collected on three to four
occasions (i.e., 3–4 days) with rich sampling during one occasion
(dosing interval) in studies 3–6. Hence, IOV was considered on
PK parameters for these four different occasions (Equation 2).




for the qth occasion. (2)
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NPatients 247 128 40 7 15 31 468
NSamples 405 128 345 180 238 639 1935
NPKobservations 810 256 690 364 478 956 3554
NSamples/pt(s) ≤4 1 ≤9 ≤ 18 ≤18 ≤ 27 –
NSamplingperiods ≤ 4 1 1 ≤ 3 ≤3 ≤3 –
20 mg QD, %pts 100 100 70 100 73 97 96
40 mg QD, %pts 0 0 30 0 27 3 4
TSFD [months], median
(range)






















72 (48–95) 61 (41–80) 52 (25–70) 51 (29–60) 51 (38–65) 51 (27–68) 64 (25–95)
CYP2D6, %pts
gUM 0 5 0 0 0 0 1
gNM 82 69 83 14 47 87 78
gIM 10 12 10 0 7 0 8
gPM 5 7 3 14 0 10 6
n.r. 3 8 4 72 47 3 7
SSRI, %pts 2.0 3.9 2.5 0 80 0 4.9
RIF, %pts 0 0 0 70 0 0 0.01
gUM, gNM, gIM, gPM: CYP2D6 genotype-predicted ultrarapid, normal, intermediate and poor metabolizer, n.r.: not reported; PK observations: plasma concentrations
of tamoxifen and endoxifen; pt(s): patient(s); QD: dosing once daily; SSRI: concomitant use of fluoxetine or paroxetine (selective serotonin reuptake inhibitors); RIF:
concomitant use of rifampicin; TSFD: time since first dose.
with typical PK parameter θk and patient individual PK
parameter θikqfor patient i = 1, . . . ,N, PK parameter k =
1, . . . ,N and occasion q = 1, . . . ,N.









) = ln(f (xij, θi)+ εij with εij = Yobsij − Ypredij .
(3)
Since tamoxifen and endoxifen PK were analyzed
simultaneously, separate but correlated RUV terms were
estimated. As only in one patient tamoxifen was quantified but
endoxifen was not, sufficient parent metabolite concentration
pairs to allow precise estimation of both RUV terms and their
correlation were available.
A study effect was introduced as additional variability term on
top of the random individual effect (IIV) (study hierarchically
above individual level, see Supplementary Figure S1 and
Equation 4) (Laporte-Simitsidis et al., 2000),
θks = θ˜k · eγks γks ∼ N (0,ϕ2k)
θksi = θks · eηik ηik ∼ N (0,ω2k) (4)
with typical population estimate θ˜k of PK parameter k,
deviation γks between θ˜k and the respective study parameter
θks and ηikthe deviation between θks and the individual PK
parameter θksi.
Covariate Submodel Development
The covariate model was developed using a full covariate model
approach (Tunblad et al., 2008; Ravva et al., 2009; Gastonguay,
2011): first, covariates were pre-selected based on specific
criteria and introduced simultaneously into a full covariate
model (for details see Supplementary Material 1, see section
“Covariate Submodel Development”). Secondly, a covariate
model refinement step was performed, selecting the most
appropriate covariate functions for the preselected covariates,
with respect to numerical and statistical evaluation criteria.
Finally, the refined full covariate model was evaluated based
on physiological plausibility of the estimated effect, statistical
significance and clinical relevance criteria using advanced
model evaluation techniques (Supplementary Material 1, see
section “Advanced Model Evaluation Diagnostics”). To explore
and quantify the reduction of unexplained variability upon
introduction of covariate effects, the statistical model with the
four levels of variability was exploited.
Determination of Patients at Risk of Subtarget
Endoxifen Concentrations
To determine the probability of endoxifen target attainment
(PTA) according to (Madlensky et al., 2011) for different patient
subgroups, tamoxifen and endoxifen concentration-time profiles
in a large tamoxifen patient population (nreplicates = 1,000
of the original database) were simulated using the final
developed model without ISV. After stratification into the
Frontiers in Pharmacology | www.frontiersin.org 4 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 5
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
FIGURE 1 | (A) CYP2D6 activity score frequency and (B) translation into CYP2D6 phenotype. gPM/gIM/gNM/gUM: poor/intermediate/normal and ultrarapid
metabolizer predicted from genotype; n.r., not reported.
respective subgroups based on CYP2D6 genotype-predicted
phenotype and comedication, the percentage of patients at
risk for subtarget endoxifen concentrations was determined per
subgroup (Equation 5).
Risk per group,% =
Number of patients per subgroup < CTH,ENDX
Total number of patients per subgroup
· 100 (5)
with CTH,ENDX = endoxifen minimum concentrations at
steady-state below the endoxifen target concentration 5.97 ng/mL
(Madlensky et al., 2011).
The simulated risk values were compared to the corresponding
observed risk values in the tamoxifen PK database.
PK Model Applications: In silico Clinical
Studies of Different Dosing Strategies
Standard vs. Two More Individualized Tamoxifen
Dosing Strategies
The developed model was applied in an in silico simulation study
to compare three dosing strategies which could subsequently
be assessed in a clinical trial: (1) Standard dosing (20 mg
tamoxifen QD), (2) CYP2D6-guided dosing, and (3) model-
informed precision dosing (Figure 2). Prior knowledge was
used in CYP2D6-guided dosing, in which the daily tamoxifen
dose was selected based on a patient’s CYP2D6 functional
activity (a priori model-informed dosing, i.e., in absence of
measured PK concentrations). Respective doses were selected
such that each CYP2D6 genotype-predicted phenotype subgroup
would achieve therapeutic target concentrations comparable
to gNM under tamoxifen standard dosing (20 mg QD).
In MIPD, after an initial CYP2D6-guided dosing period of
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FIGURE 2 | Illustration of the proposed model-informed precision dosing strategy to provide each patient with the lowest required tamoxifen dose to reach the target
concentration. ↑,↔, ↓ indicate that minimum endoxifen plasma concentrations at steady-state are well above, above and below the therapeutic target
concentration (Madlensky et al., 2011).
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4 weeks, the Bayesian approach was applied to ‘forecast’ an
individual maintenance dose: concretely, the new individual
PK information derived from three virtual TDM samples after
weeks 2, 3, and 4 was combined with patient characteristics
CYP2D6 phenotype and age to estimate patients’ individual
PK parameters using the developed model to further tailor
the dose to a patient’s needs (a posteriori model-informed
dosing). The chosen frequency and time points of virtual
TDM sampling were the result of previous simulation-
based investigations aiming to find a schedule which would
simultaneously minimize (i) the frequency of patients for whom
too low doses are selected and (ii) the time until target
concentrations are reached. Applying Bayes’ formula, individual
most likely PK model parameter estimates [maximum a posteriori
(MAP) PK parameter estimates] for every patient, given the
patient’s endoxifen observations, CYP2D6 phenotype and the
PK parameter distribution of the developed model were derived
by minimizing Equation 6. For illustration purposes, the PK
parameters and endoxifen observations are described using
the normal distribution assumption, while in the presented















In Equation 6, the left term on the right hand side describes
the sum of the squared deviations of the individual model-
predicted concentrations Cˆij from the observed concentrations
Cobs,ij of individual i at time point j, which are weighted by
the residual variance σ2 of the underlying RUV model. The
right term describes the sum of the squared deviations of
the individual PK parameter estimates θki from the typical
population parameter values θk of individual i at time point
k, which are weighted by the interindividual variance ω2k of
parameter k of the underlying IIV model. Thus, the left term
representing the likelihood of observing the PK sample is
balanced by the right term representing the prior knowledge on
PK parameter distributions. Consequently, the more information
(i.e., TDM samples) is available from a patient, the more
influential the left term on the right hand side of the equation,
so that individual observations Cobs,ij increasingly minimize the
influence of the typical population parameter values. Individual
plasma concentrations were predicted for every patient using
individual MAP PK parameter estimates for the dose range
between 5 and 120 mg QD and the lowest required dose to reach
endoxifen target threshold concentrations at steady-state was
selected for each patient. This range of maintenance tamoxifen
dose levels (5–120 mg QD) was based on the lowest available
dose in tablet form and the highest dose applied in a clinical trial,
respectively (Dezentjé et al., 2015).
Prior to the simulations, the full covariate model was modified
as such that IOV terms were removed and model parameters re-
estimated, resulting in slightly inflated IIV and RUV components.
For all simulations, a large virtual patient population (n = 10,000),
representing the distribution of patient characteristics age and
CYP2D6 AS in the clinical PK database, was used. The age
distribution in the virtual patient population was generated
using a truncated normal distribution based on the observed age
values in the clinical PK database with minimum (25 years) and
maximum (95 years) observed ages as cutoff points, respectively.
CYP2D6 genotype frequencies were extrapolated from the
clinical PK database. No interacting comedication such as SSRIs
or rifampicin was assumed to be administered. The high number
of virtual patients facilitated to observe sufficiently high numbers
of patients with rare CYP2D6 genotypes (e.g., poor and ultrarapid
metabolizers) as well as the ‘real-world’ variability in a typical
breast cancer population.
For all dosing strategies, the numbers of patients at
risk for subtarget endoxifen concentrations after 6 months
tamoxifen treatment were compared overall and for CYP2D6
genotype-predicted phenotypes separately. Furthermore, the
interindividual variability in endoxifen concentrations within the
patient population was assessed for and compared between all
dosing strategies.
RESULTS
Clinical PK Database of Tamoxifen and
Endoxifen
The PK database contained Css,minTAM and Css,minENDX from 468
adult, female breast cancer patients (see Table 1). Only eight
endoxifen concentration values (of a single patient, 0.20% of all
observations) were below the lower limit of quantification and
therefore excluded from the analysis. Tamoxifen concentration
values of this patient were still included in the analysis to
inform tamoxifen PK parameters. Most patients (96%) had been
treated with 20 mg tamoxifen QD (standard treatment). Five
patients had temporarily co-administered rifampicin (a strong
CYP3A inducer) and 23 patients had switched from paroxetine
or fluoxetine (SSRIs) comedication (potent CYP2D6 inhibitors)
to es/citalopram (antidepressant with no relevant drug–drug
interaction with tamoxifen (Binkhorst et al., 2016).
Across all studies, median Css,minTAM and Css,minENDX (of
the 20 mg dose group) were 131 and 10.7 ng/mL and ranged
widely from 3.05–448 to 0.70–45.5 ng/mL (i.e., %CVgeom of
56.3 and 84.4), respectively (Figure 3A). Considerable differences
in median CSS,min were revealed after stratification into studies
(Figure 3B); which were in part expected (i.e., studies 4 and
5 which investigated drug–drug interactions, CYP3A induction
and CYP2D6 inhibition, on PK, respectively).
Besides the influence of the DDIs (with rifampicin and SSRIs)
on Css,minTAM and Css,minENDX (Figure 3B), exploratory graphical
analyses of the PK database displayed that Css,minTAM (and
Css,minENDX) increased with age (Figure 4A), however, CSS,min
were widely scattered. In addition, Css,minENDX increased with
increasing CYP2D6 activity, displayed by the ordered categorical
covariate CYP2D6 activity score (Figure 4B).
The PK database was representative of a Caucasian CYP2D6
population (Gaedigk et al., 2008) containing 5.8% and 1.3% of the
rare gPM (AS: 0) and gUM (AS: 2.5–3), respectively (Figure 1).
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FIGURE 3 | Minimum concentrations of tamoxifen (TAM) and endoxifen (ENDX) at steady-state (CSS,min) in patients treated with 20 mg tamoxifen once daily: (A) all
studies combined and (B) stratified by study.
FIGURE 4 | Minimum concentrations of tamoxifen (TAM) and endoxifen (ENDX) at steady-state (CSS,min) at the first visit (n = 440 patients) (A) across age and
(B) CYP2D6 activity scores. Patients with rifampicin or paroxetine/fluoxetine comedication were excluded (n = 14). Patients with missing age (n = 6) and missing
CYP2D6 genotype data (n = 27) were additionally excluded for (A,B), respectively. Solid line: smoothing spline; Area around spline: 95th confidence interval.
Patients without CYP2D6 information (n = 32, 6.84%)
were classified as normal metabolizers (i.e., CYP2D6 AS: 2),
representing the most frequent group in a Caucasian population
and thus, the reference category. For patients with missing
age information (n = 10, 2.14%), the population median was
imputed. For missing comedication data (n = 376, 80.3%
for rifampicin; n = 1, 0.214% for SSRIs), no comedication
was assumed.
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Joint PK Model and Characterization of
Influential Factors on Tamoxifen and
Endoxifen PK
A one-compartment model with first-order absorption with
lag time and first-order elimination for tamoxifen PK, linked
to a one-compartment model with first-order formation
(from tamoxifen compartment) and first-order elimination
for endoxifen, was selected as appropriate and stable PK
model with respect to its context of use (Figure 5). Since
no intravenous data was available and hence absolute
bioavailability (F) remained unknown, the PK model was
parameterized in terms of relative clearances (CL20/F; CL23/F;
and CL30/F) and relative central volume of distribution
(VTAM/F; VENDX/F). Furthermore, endoxifen PK parameter
values (CL30/F = 5.1 L/h and VENDX/F = 400 L) were informed
and used from a clinical study administering endoxifen only
(Ahmad et al., 2010b).
Parameter estimates and their corresponding relative standard
errors (RSEs) and confidence intervals (CIs), as measures
of uncertainty, are summarized in Table 2, left. The typical
population PK parameter estimates (95% CI) given the reference
patient (CYP2D6 activity score 2/fast-normal metabolizer gNM-
F, 65 years old, no comedication with rifampicin as CYP3A
inducer or paroxetine/fluoxetine as selective serotonin-reuptake
inhibitors and CYP2D6 inhibitors) were 5.77 L/h for CL20/F,
0.493 L/h for CL23/F and 1120 L for VTAM/F. All structural
FIGURE 5 | Schematic representation of the joint tamoxifen and endoxifen PK
model including covariate relationships. CL20/F: relative clearance of
tamoxifen; CL23/F: relative formation of endoxifen; CL30/F: relative clearance
of endoxifen; CYP2D6 AS: CYP2D6 activity scores as ordered categorical
covariate from 0 to 3 in increments of 0.5; ENDX: endoxifen compartment
with VENDX /F; ka: absorption rate constant; RIF: rifampicin comedication as
categorical covariate (proportional change of respective structural PK
parameter); SSRI: paroxetine/-fluoxetine comedication as categorical
covariate (proportional change of respective structural PK parameter); Gut:
tamoxifen dose in gut compartment; TAMC: central tamoxifen compartment
with VTAM/F; tlag: lag time; VX /F: relative volume of distribution of x, being
either tamoxifen or endoxifen; bold: estimated parameters [other parameters
fixed to values from literature (Ahmad et al., 2010b)].
parameters were estimated with high precision (RSEs ≤ 16.5%).
Individual information on CL20/F and CL23/F was sufficient
to estimate IIV components and consequently, identify sources
of variability. As both processes are mediated via different
CYP enzymes (CL20/F mostly via CYP3A4, CL23/F mostly via
CYP2D6), a correlation between both IIV components seemed
unlikely. However, as both are competing processes, a correlation
between the IIV parameters for CL20/F and CL23/F could
be possible and was thus evaluated. Including the correlation
term decreased the objective function value by 3.9 points.
However, the correlation was low and resulted in increased
relative standard errors in the structural parameters. Thus, it
was decided to not include a correlation between IIV parameters
for CL20/F and CL23/F. IIV components for VTAM/F, VENDX/F,
lag time and the absorption rate constant were not supported
by the data. The effects of the preselected covariates age,
CYP2D6 activity score and comedication on CL20/F and CL23/F,
were strong (clinically relevant, s. Figures 6A,B) and precisely
(RSE: 3–42%) identified:
Age
The average population estimate for the power model effect
of age on tamoxifen clearance CL20/F was −0.886 (95% CI:
−1.06, −0.721) (Table 2), indicating CL20/F decreased with age:
Compared to the 65 years old reference patient, the relative
eliminating efficacy was twofold higher in patients of 30 years of
age and 25% lower in patients of 90 years (Figure 6A).
CYP2D6 Activity Score
The lower the CYP2D6 activity score (AS), the lower the
endoxifen formation CL23/F: Poor (AS: 0) and intermediate
metabolizers (AS: 0.5) showed a 72.2% (95% CI: 67.4–76.9%)
and 51.0% (95% CI: 40.6–60.3%) reduced formation efficiency,
respectively, while ultrarapid metabolizer (AS ≥ 2.5) displayed
a 53.3% (95% CI: 10.8–91.4%) increased CL23/F (Table 2). AS
1 and 1.5 displayed a fractional decrease from CL23/F reference
value of 32.3% (95% CI: 24.9–39.2%) and 21.1% (95% CI: 9.94–
32.3%), respectively.
Fractions of tamoxifen metabolized to endoxifen (FM),
calculated as
FM,% = CL23/F
(CL23/F + CL20/F) · 100 (7)
were 7.87% in patients with reference category AS 2 (gNM-F).
In intermediate (AS: 0.5) and poor (AS: 0) metabolizers, the FM
was reduced by 48.9 and 70.5%, respectively, while in ultrarapid
metabolizers the FM was higher by 47.4%.
Comedication: CYP-Mediated Drug Interaction
Although the number of patients who had rifampicin or SSRIs
coadministered was small (0.01 and 4.9% of the total population,
respectively), the covariate effects were strong (clinically relevant,
s. Figures 6A,B) and precisely (RSE: 13–42%) estimated using
fractional change models: Rifampicin intake caused a substantial
increase of 6.51-fold in CL20/F (95% CI: 5.00–8.11) and of
1.18-fold in CL23/F (95% CI: 0.548–1.97) (Figure 6B). Due to
the high CL20/F during rifampicin coadministration, the FM
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TABLE 2 | Parameter estimates of the joint parent-metabolite PK model of tamoxifen and endoxifen using the clinical PK database.
Parameter [unit] Estimate RSE,% 95% CI
Fixed effects ka [1/h] 1.78 14.2 1.40 2.36
tlag [h] 0.389 5.80 0.344 0.431
VTAM/F [L] 1120 16.4 861 1599
CL30/F [L/h] 5.10 fixed
VENDX/F [L] 400 fixed
CL20/F [L/h] (Ref.) 5.77 1.98 5.54 6.00
VTAM/F_Rifampicin* 0.581 34.4 0.167 0.948
CL20/F_Rifampicin* 6.51 11.8 5.00 8.11
CL20/F_Age** −0.886 9.73 −1.05 −0.72
CL23/F [L/h] (Ref.) 0.493 3.17 0.461 0.524
CL23/F_AS: 0* −0.722 3.40 −0.769 −0.674
CL23/F_AS: 0.5* −0.510 10.2 −0.603 −0.406
CL23/F_AS: 1* −0.323 11.6 −0.392 −0.249
CL23/F_AS: 1.5* −0.211 26.6 −0.323 −0.099
CL23/F_AS: 2.5-3* 0.533 41.4 0.108 0.944
CL23_SSRI* −0.654 5.32 −0.715 −0.578
CL23_Rifampicin* 1.18 30.2 0.548 1.96
Random effects IIV CL20/F 0.148 (39.9% CV) 8.98 0.122 0.172
IIV CL23/F 0.201 (47.2% CV) 9.20 0.168 0.238
IOV CL20/F 0.0222 (15.0% CV) 28.5 0.0133 0.0371
IOV CL23/F 0.0289 (17.1% CV) 18.3 0.0209 0.0414
RUV tamoxifen 0.0260 (16.2% CV) 5.76 0.0236 0.0295
COVARRUVtam−RUVendx 0.0169 7.28 0.0148 0.0195
RUV endoxifen 0.0267 (16.5% CV) 6.19 0.0227 0.0291
*Fractional change covariate models, see Supplementary Material Equations 1 and 8; **Power covariate model, see Supplementary Material Equation 4; AS: CYP2D6
activity score from 0 to 3 with increments of 0.5; CI: 95% confidence interval for the estimates derived from sampling importance resampling method; COVAR: covariance;
CL20/F: relative clearance of tamoxifen; CL23/F: relative formation of endoxifen; CL30/F: relative clearance of endoxifen; IIV: interindividual variability; IOV: Inter-occasion
variability; ka: absorption rate constant; CV: %coefficient of variation of estimate; Fixed: parameter fixed based on data from a study administering endoxifen only (Ahmad
et al., 2010b); Rifampicin: CYP3A inducer comedication; RSE: %relative standard error = (SE/Estimate)·100; RUV: residual unexplained variability; SSRI: fluoxetine or
paroxetine comedication (CYP2D6 inhibitors); tlag: absorption lag time; VTAM/F, VENDX/F: relative central volume of distribution of tamoxifen and endoxifen, respectively.
(Equation 2) was substantially reduced to 2.42% in a typical
NM (AS = 2) compared to a typical NM patient not taking
rifampicin. SSRIs coadministration in a typical NM led to a 65.4%
decrease in CL23/F (95%CI: 57.8–71.5%) (Table 2) translating
into a low FM (2.89%).
Joint PK Model Evaluation
The visual predictive checks displayed that the simulated
median, 25th-75th (dark shaded area) and 5th-95th (light
shaded area) prediction intervals were in line with the observed
concentrations over time after last dose at PK steady-state
for tamoxifen and endoxifen (Supplementary Figure S2).
Observed CSS,min around 24 h were well captured by the model-
predicted CSS,min across subgroups and doses, as highlighted
by the gray area in the VPC plots. The visual predictive box-
whisker plots (Figure 7) revealed that the joint tamoxifen
and endoxifen PK model reflected the observed Css data well
when stratified by the four ‘traditional’ CYP2D6 phenotype
categories (patients with AS = 1 classified as gNM) without and
with CYP-mediated comedication intake, i.e., CYP3A-inducer
rifampicin and CYP2D6-inhibiting SSRIs (Figures 7A,B).
A slight overprediction of CSS,minENDX with co-administered
rifampicin within the CYP2D6 gNM subgroup was apparent.
An additional subdivision of the four ‘traditional’ CYP2D6
phenotype categories into the seven CYP2D6 AS subgroups
revealed a good predictive performance as displayed in the VPC
boxplots (see Supplementary Figure S3).
Reduction of Unexplained Variability of
Several Levels
Several levels of variability were dissected and precisely quantified
by sequentially building up the hierarchical variability structure
from two to four random variability levels (RUV, IIV, IOV, and
ISV, see Table 1). IIV, IOV, and ISV were partly explained by
the investigated covariates. By excluding covariate effects one by
one from the full covariate model including 4-levels of variability,
absolute and relative fractions of variability explained by the
respective covariates were determined:
Interoccasion Variability
Large fractions, 39.8% and 28.8%, of the total IOV in CL20/F
and CL23/F, respectively, were attributed to the introduction
of the time-varying comedication covariate effects, rifampicin
and SSRIs (Figure 8A). Once the effect of the CYP3A inducer
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FIGURE 6 | Magnitude and precision of covariate effects age, CYP2D6 activity score and selective serotonin -reuptake inhibitor (SSRI: paroxetine/fluoxetine;
CYP2D6 inhibitors) (A) or rifampicin (RIF; CYP3A inducer) (B) on tamoxifen clearance (CL20/F ) and endoxifen formation (CL23/F) relative to the reference patient
(Ref.), i.e., CYP2D6 normal metabolizer (AS: 2), 65 years old, no coadministered RIF or SSRI.
rifampicin was implemented on CL20/F, the corresponding
IOV reduced from 24.9% CV to 14.9% CV (Figure 8B).
Similarly, considering the effect of coadministered potent
CYP2D6 inhibitors SSRIs on CL23/F reduced the corresponding
IOV from 26.4% CV to 17.1% CV.
Interindividual Variability
Of the total IIV in CL23/F, 25% (22.5% and 3.01%) were
explained by the inclusion of the covariates CYP2D6 AS and
SSRI comedication, respectively (Figure 8A), reducing the IIV
of CL23/F by 35.2% from 63.3% CV to 47.2% CV (Figure 8B).
A small fraction (1.35% and 0.54%) of total IIV in CL20/F
was explained by the covariates age and CYP2D6 phenotype
(Figure 8A), respectively.
Interstudy Variability
Upon covariate introduction, the total ISV reduced by more
than half (51.8%) from 31.2% CV to 16.1% CV. Specifically,
the addition of the covariate effects of age and rifampicin
comedication reduced the total ISV on tamoxifen clearance
(CL20/F) by 27.2% and 21.2%, respectively (Figure 8A).
Overall, large fractions of unexplained variability in IOV and
ISV were explained upon covariate introduction resulting in CV
values <18%. Although covariates explained considerable parts
of IIV in CL23/F, IIVs on tamoxifen clearance (CL20/F) and
endoxifen formation (CL23/F) remained large with CV of 37.1%
and 47.2%, respectively.
Determination of Patients at Risk of
Subtarget Endoxifen Concentrations
The overall risk of subtarget endoxifen concentrations was
similar in the observed (28.9%) and the simulated (27.1%)
population, respectively. To identify subgroups at highest
risk, the observed and simulated patient populations were
stratified according to comedication intake and CYP2D6 AS.
Predicted endoxifen concentrations at steady-state declined
with decreasing CYP2D6 enzyme activity (from CYP2D6
ultrarapid, gUM, to poor metabolizers, gPM) and upon CYP-
mediated comedication intake (CYP3A-inducer rifampicin and
CYP2D6-inhibiting SSRIs) mimicking the overlaid observed
data (Figure 7B).
CYP2D6 poor metabolizer (gPM), patients on rifampicin or
on respective SSRIs were identified as subgroups at high risk of
subtarget endoxifen concentrations, as indicated by the fractions
predominately below the therapeutic threshold (dashed line in
Figure 6, middle panel). For these subgroups, risk values were
>76% with predicted risk values being well in line with the
observed values in the PK database (Figure 7C).
CYP2D6 normal (gNM) and ultrarapid metabolizers (gUM)
were at lower risk with 19.0% (95% CI: 15.3–23.5) and 0.0%
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FIGURE 7 | Predicted (boxes) and observed (×) concentrations at steady-state (CSS) of tamoxifen (TAM) (A) and endoxifen (ENDX) (B) dose-normalized and
stratified by CYP2D6 phenotype categories and CYP-mediated coadministration as well as corresponding % non-attainment of therapeutic target endoxifen
concentration (C).
(95% CI: 0.0–16.7), respectively. However, almost half of CYP2D6
intermediate metabolizers (gIM) were at risk of subtarget
endoxifen concentrations with 42.3% (95% CI: 26.9–59.6). gPM
and patients that co-administered CYP2D6-inhibiting SSRIs
(paroxetine/fluoxetine) revealed similar risk values with 75.6%
(95% CI: 57.8–88.9) and 76.5% (95% CI: 55.9–91.2), respectively.
100% risk of subtarget endoxifen concentrations were displayed
in gIM and gPM that co-administered CYP2D6-inhibiting SSRIs,
as well as in patients co-administering rifampicin independent of
their CYP2D6 phenotype.
Standard vs. Two More Individualized
Tamoxifen Dosing Strategies
Three dosing strategies were compared using a simulation
approach applying the previously developed joint parent-
metabolite pharmacokinetic model. In the standard dosing group
(strategy 1), 8 out of 10 gPM (80.2%) and almost half (45.2%) of
gIM were at risk of subtarget endoxifen concentrations (Figure
9A). Overall, 22.2% of the virtual population were at risk in the
standard dosing group. For CYP2D6-guided dosing (strategy 2),
daily doses of 40 mg in gIM and 60 mg in gPM were appropriate
to reduce risks for subtarget endoxifen concentrations to
10.4% and 20.3%, respectively, and to obtain similar endoxifen
concentrations as observed in gNM at 20 mg daily doses
(Figure 9B). However, a large variability in CSS,minENDX within
the CYP2D6 sub-populations was observed (%CV > 59%, see
Figure 9B and Table 3). Thus, CYP2D6-guided dosing resulted
in very high concentrations of tamoxifen and its metabolites in
some patients. MIPD (strategy 3) facilitated target attainment in
almost all patients. Concretely, the risk was reduced to 6.88% in
gNM, 7.67% in gIM and 11.0% in gPM. Moreover, a narrow range
in CSS,minENDX was achieved within and across all subpopulations
(Figure 9C and Table 3). As a consequence, a large dose spread
was obtained (see Figure 10): while for the majority of gIM and
gPM, increased doses of up to 40 mg or 60 mg QD were sufficient
Frontiers in Pharmacology | www.frontiersin.org 12 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 13
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
FIGURE 8 | (A) Relative and (B) absolute fractions of variability (% coefficient of variation) explained by covariates on tamoxifen (TAM) clearance CL20/F and
endoxifen (ENDX) formation CL23/F across the three levels of variability: Interindividual (IIV), interoccasion (IOV), and interstudy (ISV).
FIGURE 9 | Patients at risk of subtarget endoxifen concentrations across
dosing strategies. Simulated minimum steady-state concentrations of
endoxifen (CSS,min) in CYP2D6 genotype-predicted normal/ultrarapid
metabolizers (gNM), intermediate (gIM) and poor metabolizer (gPM) across
dosing strategies (A) standard, (B) CYP2D6-guided and (C) model-informed
precision dosing (MIPD) (neach = 10,000). Dashed horizontal line: endoxifen
therapeutic threshold (Madlensky et al., 2011); boxes: interquartile range
(IQR), including median; whiskers: range from hinge to lowest/highest value
within 1.5 IQR; points: data outside whiskers.
to attain therapeutic endoxifen concentrations, the majority of
gNM were adequately treated with the standard dose. Only in
rare cases, gPM required high doses up to 120 mg QD. Of note,
the PK target threshold was achieved with lower doses than the
CYP2D6-guided dose for a considerable number of gNM (5 mg
or 10 mg: 45.8%), gIM (<40 mg: 51.8%) and gPM (<60 mg:
57.2%) when compared with dosing strategy 2. Most importantly,
in total 92.1% of patients achieved therapeutic CSS,minENDX in
the MIPD group whereas it was only 84.0% in CYP2D6-guided
dosing and 77.8% in standard dosing.
DISCUSSION
A parent-metabolite PK model was successfully developed,
jointly describing tamoxifen and its clinically most important
metabolite endoxifen, following continuous once daily oral
tamoxifen dosing. The integrated analysis of six pooled clinical
studies identified a patient’s CYP2D6 genotype as predictor for
CSS,min ENDX and as a highly informative covariate for potential
dose adjustments at tamoxifen treatment initiation. Furthermore,
drug–drug interactions with strong CYP2D6 inhibitors or
strong CYP3A4 inducers were shown to dramatically reduce
endoxifen concentrations, which might impede tamoxifen
treatment success and should thus be evaluated in a dedicated
prospective clinical trial. Most importantly, the low observed
IOV in contrast to the high observed IIV demonstrates the
potential of individualized dosing for treatment optimization. To
provide useful guidance in clinical practice on the one hand,
and a potentially more successful treatment for the individual
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TABLE 3 | Comparison of clinical trial simulations of standard vs. CYP2D6-guided- vs. model-informed precision dosing.
(1) Standard dosing (2) CYP2D6-guided dosing (3) Model-informed precision dosing
CYP2D6 gNM gIM gPM All gNM gIM gPM All gNM gIM gPM All
npatients 8,650 770 580 10,000 8,650 770 580 10,000 8,650 770 580 10,000
Dose (mg)a 20 (−) 20 (−) 20 (−) 20 (−) 40 (−) 60 (−) 20 (5–120) 40 (5–120) 60 (10–120)
CSS,minENDX
−Median 12.4 6.54 3.44 12.4 16.4 10.3 8.49 8.37 7.55
−IQR 7.24–16.7 4.22−9.73 2.16−5.42 7.24−16.7 10.9−24.4 6.48−16.3 7.06–10.2 6.99–10.0 6.64–9.00
−CV,% 63.8 59.0 72.3 61.1 64.9 72.3 23.9 23.9 24.9
nrisk, % 16.2 45.2 80.2 22.2 16.2 10.4 20.3 16.0 6.88 7.67 11.0 7.19
For all three scenarios, the same virtual tamoxifen population (n = 10,000) was used. a: fixed or median dose (range); allowed dose range 5–120 mg (min-max); CSS,minENDX:
minimum endoxifen steady-state concentration in ng/mL; CV: coefficient of variation assuming log-normal distributed CSS,minENDX; all: total population if respective
scenario; IQR: inter-quartile range; gNM/gIM/gPM: normal incl. ultrarapid/intermediate/poor metabolizer; nrisk: patients at risk of subtarget endoxifen concentrations; PTA:
probability of endoxifen PK target-attainment.
FIGURE 10 | Dose spread within and across CYP2D6 normal/ultrarapid,
intermediate and poor metabolizers, applying model-informed precision
dosing. gPM/gIM/gNM/: poor/intermediate/normal incl. ultrarapid metabolizer,
predicted from genotype.
tamoxifen patient on the other hand, a model-informed precision
dosing strategy as demonstrated by the investigated simulation
study might be most appropriate.
The CYP2D6 AS was identified as a strong predictor of
endoxifen exposure, as its impact on endoxifen concentrations
was precisely estimated and large, relevant effect sizes were
displayed (Figure 6). Importantly, the model successfully
predicted increasing CL23/F with increasing CYP2D6 AS and
corresponding percentage risk values across the full range
of CYP2D6 activity scores (only lumping AS groups of 2.5
and 3) (Supplementary Figure S2). With almost all patients
displaying subtarget endoxifen concentrations, gPM (AS: 0)
were identified as patients at highest risk, followed by gIM
(AS: 0.5) with around half of patients at risk. These findings
are consistent with previous findings in the literature (Borges
et al., 2006; Madlensky et al., 2011; Mürdter et al., 2011;
Schroth et al., 2017) and substantiate the important role of
CYP2D6 in tamoxifen pharmacokinetics. As patients’ CYP2D6
genotype is easily determined or already accessible prior to
treatment start, it should be considered for initial dose selection.
Neglecting this information might cause several additional and
unnecessary steps of dose refinements until the endoxifen target
concentration is met.
Integrated data from patients comedicated with rifampicin
or SSRIs revealed substantial alterations on the PK of tamoxifen
and endoxifen. Most remarkably, CSS,minENDX fell below the
therapeutic threshold during rifampicin coadministration,
irrespective of CYP2D6 phenotype (Figure 8). During
strong CYP2D6-inhibitor comedication, the inhibition of
endoxifen formation was substantial (−65%) resulting in gNM
showing FM comparable to CYP2D6 gPM (2.32%) and gNM
coadministering rifampicin (2.42%). This was not surprising,
since our observations were well in line with reports from
literature (Stearns et al., 2003; Jin et al., 2005; Borges et al., 2006).
These findings call for action to reduce the risk of CYP-mediated
DDIs in tamoxifen therapy, as they may hamper clinical efficacy
(Hansten, 2018).
While all identified covariates have been described before,
we for the first time evaluated and quantified their impact
jointly in a large real-world patient cohort. In addition, our
model-based analysis enabled to determine and precisely estimate
for each covariate the specific mechanism influenced (i.e.,
endoxifen formation by CYP2D6 AS and tamoxifen clearance by
rifampicin coadministration).
A particular strength of our study was the large and
diverse tamoxifen population which enabled to dissect and
quantitatively characterize the PK variability of tamoxifen and
endoxifen across studies (i.e., ISV), between (i.e., IIV) and within
patients (i.e., IOV and RUV). As expected, large fractions of
IOV were explained by the time-varying covariates (rifampicin
and SSRI comedication) resulting in a low IOV in the final
NLME-PK model (≤17.1% CV). Thus, within a patient, plasma
concentrations of tamoxifen and endoxifen were relatively
constant over time and therefore predictable for future treatment.
In contrast, large unexplained IIV in the PK of tamoxifen and
endoxifen, as reflected by the large IIV values on tamoxifen
elimination (39.9% CV) and endoxifen formation (47.2% CV),
Frontiers in Pharmacology | www.frontiersin.org 14 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 15
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
was observed. These individual differences in PK may lead to
differences in clinical response. Hence, to ensure therapeutic
CSS,minENDX in the individual patient [applying the proposed
threshold by Madlensky et al. (2011)], a dosing strategy that
considers a patient’s individual PK might be most promising.
Model-informed precision dosing facilitates the systematic and
quantitative consideration of various influential factors on the
PK of tamoxifen, i.e., CYP2D6 functional activity, patient age
and comedication, in the individual dose selection process.
A low IOV [<20% (Abrantes et al., 2019)] and a high IIV
enable to predict drug concentrations upon potential dose
adaptations (Karlsson and Sheiner, 1993; Wallin et al., 2010;
Abrantes et al., 2019) and are thus important predictors
for added value by MIPD, as it was demonstrated in our
simulation study.
In this simulation study, the currently practiced ‘one-
dose-fits-all’-strategy, in which all patients receive 20 mg
tamoxifen daily irrespective of their CYP2D6 AS, performed
poor with respect to both (i) endoxifen target attainment
and (ii) the large interindividual variability of CSS,minENDX .
Both alternative strategies, CYP2D6-guided dosing and MIPD,
were superior in scope of the probability of target attainment.
Applying MIPD reduced the risk for subtarget CSS,minENDX
by 2/3 compared to standard dosing. This corresponds to
a number needed to treat (NNT) of 7, meaning that for
one additional patient to reach target CSS,minENDX , only 7
patients would have to be treated applying MIPD instead
of standard dosing. While MIPD was most beneficial for
gIM and gPM (NNT of 3 and 2, respectively), there was
also a substantial effect for gNM (NNT: 11). While the
CYP2D6 AS can guide initial tamoxifen treatment as predictive
covariate, TDM samples after 2, 3, and 4 weeks of CYP2D6-
guided tamoxifen treatment may further individualize the
optimal tamoxifen dose. Furthermore, MIPD results in
a narrow CSS,minENDX range even among patients with
diverse CYP2D6 functionality, due to the wide spread of
individually selected doses.
TDM-supported dosing without modeling and simulation
may be considered as more intuitive and more versatile, but
we have to consider that without modeling and simulation
in general (i) steady-state has to be attained first and (ii)
TDM samples have to be taken at exact time points to
be reliable. We have previously reported that fluctuations of
CSS,minENDX within a dosing interval are minimal (Klopp-
Schulze et al., 2018), which in this special case allows to
take TDM samples at any time during a steady-state dosing
interval. Nevertheless, in TDM ‘only’ it is generally crucial
to obtain samples at predefined timepoints (mostly Cmin)
to be able to compare measured with target concentrations.
In contrast, deviations from scheduled sampling times are
unproblematic in MIPD as long as exact sampling timepoints
are documented. Even though TDM-supported tamoxifen dosing
without modeling and simulation is feasible with respect to
sampling timepoints, it takes about 1 and 3 months, respectively,
for tamoxifen and endoxifen, to reach steady-state and a
considerable proportion of patients will need several months to
reach target endoxifen steady-state concentrations. Furthermore,
dose adaptations based on TDM ‘only’ are more sensitive
to data errors and thus only precise if multiple samples
per patient are available. Calculations of PK target indices
to derive dose recommendations from TDM samples take
additional time, efforts and clinical staff with appropriate skills
to perform the analysis (using adequate software programs).
Finally, the interpretation of TDM results and translation into a
dose recommendation requires specific knowledge and thereby
depends on the attending clinician/clinical pharmacist. MIPD,
in contrast, not only protects against measurement errors
and process noise but also enables to incorporate relevant
predictors, i.e., genetic information, and requires fewer samples
by considering optimal sampling time windows (‘optimal
design’) (D’Argenio, 1981). By combining prior knowledge
(integrated in the model), patient characteristics (available before
treatment start) and patient individual PK information (from
TDM samples), therapeutic concentrations can be achieved
earlier and with higher probability, compared to standard or
TDM-based dosing strategies (Dezentjé et al., 2015; Fox et al.,
2016). The feasibility of our proposed MIPD framework might
be challenged as we propose doses as low as 5 mg and as
high as 120 mg, both requiring off-label use of tamoxifen. Even
though we made sure to only consider off-label doses which
had been tested and proven safe in clinical studies (Dezentjé
et al., 2015; DeCensi et al., 2019), additional information on
the efficacy and safety of off-label tamoxifen doses has to be
generated in clinical trials before their use can be recommended
in clinical practice.
Of note, tamoxifen’s complex PK is ascribed to its
physicochemical properties but also causes challenges from
a bioanalytical perspective. More than one decade after the
discovery of the active metabolite endoxifen, standardized
validated bioanalytical methods have yet to be established to
assure comparable PK and PGx results (Gaedigk et al., 2008;
Brauch et al., 2013; Ratain et al., 2013; Schroth et al., 2017).
This probably plays not only a role for the characterization of
IIV but also of ISV. These – yet undetermined – interstudy
discrepancies have also been identified when comparing
predictions from two published NLME-PK models of tamoxifen
and endoxifen (Klopp-Schulze et al., 2015, 2018). These PK
models characterized the PK of the underlying clinical data,
which largely differed in patient size, distribution of un-
/documented patient factors, study design and bioanalytical
assessment. These aspects are important to be aware of and
need to be carefully considered when re-purposing a PK
model based on one dataset, e.g., for simulations or model-
informed dosing. To obtain a more complete representation
of the ‘real-world’ patient population in clinical routine, it is
appealing to integrate clinical data from multiple studies into a
single NLME-PK model (meta-analysis approach), as has been
done in this work.
Importantly, it should be considered that interindividual
variability in clinical outcome might not only be explainable by
variability in PK but also by variations in pharmacodynamics.
The latter contributes to the difficulties observed in
reproducing and confirming the relationship between endoxifen
exposure and clinical outcome. Therefore, carefully designed
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prospective studies are needed, jointly assessing PK and
clinical endpoints (breast cancer progression/recurrence,
adverse drug reactions) and/or an appropriate biomarker
[e.g., tumor size, circulating tumor cells, Ki67 antigen
(Yerushalmi et al., 2010) over time (Ribba et al., 2014; Bender
et al., 2015; Buil-Bruna et al., 2016)] in a representative,
well-defined tamoxifen patient population. In this respect
and as demonstrated in the presented simulation studies,
modeling and simulation provides the potential to elucidate
not only the complex PK behavior of tamoxifen and its
metabolites, but also to assess the drug and/or metabolites
exposure-response relationship.
Of note, endoxifen as own compound is currently in clinical
development (Ahmad et al., 2010a,b; Goetz et al., 2017) and
could supersede tamoxifen as antihormonal breast cancer drug
in the future. Given the independence of endoxifen formation by
CYP2D6 and the opportunity to bypass the complex metabolism
of tamoxifen, this development seems straightforward and
promising. However, the relevance of tamoxifen itself and its
other metabolites for its efficacy has still not been fully elucidated.
As a first step, the prospective, multicentre TAMENDOX study
(NCT03931928) (TAMENDOX, 2020) will assess the feasibility of
genotype- and phenotype-guided supplementation of tamoxifen
standard therapy with endoxifen to reach target CSS,minENDX .
Future clinical studies are warranted to show if endoxifen is
superior to model-informed precision dosed tamoxifen with
respect to clinical outcomes.
Despite the large potential of MIPD, it is important to
mention that the relationship between CYP2D6 genotype and/or
endoxifen concentrations and breast cancer recurrence is still
controversial and has been the subject of intensive debates
amongst researchers and clinicians since almost a decade
(Brauch et al., 2013; Binkhorst et al., 2015b; Zembutsu et al.,
2017; Neven et al., 2018). A recent study by Sanchez-Spitman
et al. (2019), in which no relationship between CYP2D6
genotype or endoxifen concentrations and clinical outcome
could be established, revived the discussion once again. Several
researchers criticized large methodological shortcomings of this
work (Braal et al., 2019; Brauch et al., 2019; Goetz et al.,
2019), i.e., low power of only ∼30% to detect the proposed
exposure-response relationship, lack of information on co-
medication, and limited/inadequate PK sampling (de Vries
Schultink, 2019). A common element of all responses was
the urgent call for a well-designed prospective, randomized
clinical trial with sufficient power to investigate the proposed
exposure-response relationship. Simulations of observational
and randomized clinical trials to evaluate the feasibility of
TDM for endoxifen showed that at least low thousands of
patients would have to be followed for 15 years or longer
in observational or randomized controlled trials, respectively,
for sufficient power (>0.8) to confirm the hazard ratio
of 0.71 (de Vries Schultink, 2019) reported by Madlensky
et al. (2011) and in line with Saladores et al. (2015)
and Gong et al. (2013).
Based on the still considerable controversy over the
relationship between CYP2D6 genotype and/or endoxifen
concentrations and clinical outcome, our theoretical in silico
simulation work suggests as next step the investigation of our
proposed MIPD framework in comparison to the conventional
‘one-dose-fits-all’ dosing strategy in a well-designed and -
powered prospective clinical trial setting, allowing to evaluate
the ‘real-world’ clinical benefit (i.e., the possibility of achieving
recduced breast cancer recurrence rates) and (long-term)
safety of MIPD for tamoxifen. Furthermore, as treatment
outcome cannot be explained by endoxifen concentrations
alone, other relevant factors contributing to the overall
variability in clinical outcome need to be identified and
appropriately characterized.
In summary, this presented model provides an appropriate
framework to (i) identify patients at risk of subtarget endoxifen
concentrations prior to tamoxifen treatment start, (ii) aid an
upfront dose adaptation based on a patient’s CYP2D6 geno-
/phenotype, and (iii) guide dose refinements early after treatment
start based on TDM samples, as well as (iv) monitor and detect
discrepancies, due to, e.g., non-adherence or DDIs, allowing
enhanced patient care and improved clinical benefits.
The outlined modeling and simulation framework might
be well translatable and applicable to further oral anti-
anticancer drugs (OADs) exhibiting similar challenges.
A model-informed precision dosing tool for a collection
of OADs could conceivably be of high utility to aid
rational dose decision-making in routine oncology clinical
practice, e.g., by expanding existing model-based dose
decision support tools [such as TDMx (Wicha et al.,
2015) or InsightRx (InsightRx, 2019)] to the therapeutic
area of oncology.
DATA AVAILABILITY STATEMENT
The datasets for this manuscript are not publicly available
because patients did not provide consent for their data being
shared in a public database and this purpose was also not included
in the original IRB proposal. Requests to access the datasets
should be directed to the corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed
and approved by the respective ethics committees as
this is a pooled meta-analysis of original studies. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
LK-S, AM-S, MJ, and CK contributed conception and design
of the presented work and discussed the results. LK-S
created the database. LK-S and AM-S performed the modeling
and simulation analyses. LK-S and AM-S wrote the first
draft of the manuscript. MJ, PN, RM, and SK contributed
Frontiers in Pharmacology | www.frontiersin.org 16 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 17
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
to sections of the manuscript. All authors contributed to
manuscript revision, read and approved the submitted version.
ACKNOWLEDGMENTS
We thank the High-Performance Computing Service of ZEDAT
at Freie Universität Berlin (https://www.zedat.fu-berlin.de/HPC/
Home) for computing time. We acknowledge support by the
Open Access Publication Initiative of Freie Universität Berlin.
This work has been in parts presented in the doctoral thesis of
LK-S (Klopp-Schulze, 2018).
SUPPLEMENTARY MATERIAL




Abrantes, J. A., Jönsson, S., Karlsson, M. O., and Nielsen, E. I. (2019).
Handling interoccasion variability in model-based dose individualization using
therapeutic drug monitoring data. Br. J. Clin. Pharmacol. 85, 1326–1336. doi:
10.1111/bcp.13901
Ahmad, A., Ali, S. M., Ahmad, M. U., Sheikh, S., and Ahmad, I. (2010a). Orally
administered Endoxifen is a new therapeutic agent for breast cancer. Breast
Cancer Res. Treat 122, 579–584. doi: 10.1007/s10549-009-0704-7
Ahmad, A., Shahabuddin, S., Sheikh, S., Kale, P., Krishnappa, M., Rane, R. C., et al.
(2010b). Endoxifen, a new cornerstone of breast cancer therapy: Demonstration
of safety, tolerability, and systemic bioavailability in healthy human subjects.
Clin. Pharmacol. Ther. 88, 814–817. doi: 10.1038/clpt.2010.196
Barginear, M. F., Jaremko, M., Peter, I., Yu, C., Kasai, Y., Kemeny, M., et al.
(2011). Increasing tamoxifen dose in breast cancer patients based on CYP2D6
genotypes and endoxifen levels: Effect on active metabolite isomers and the
antiestrogenic activity score. Clin. Pharmacol. Ther. 90, 605–611. doi: 10.1038/
clpt.2011.153
Bender, B. C., Schindler, E., and Friberg, L. E. (2015). Population pharmacokinetic-
pharmacodynamic modelling in oncology: A tool for predicting
clinical response. Br. J. Clin. Pharmacol. 79, 56–71. doi: 10.1111/bcp.
12258
Binkhorst, L., Bannink, M., de Bruijn, P., Ruit, J., Droogendijk, H., van Alphen,
R. J., et al. (2016). Augmentation of Endoxifen Exposure in Tamoxifen-Treated
Women Following SSRI Switch. Clin. Pharmacokinet 55, 249–255. doi: 10.1007/
s40262-015-0315-x
Binkhorst, L., Kloth, J. S. L., de Wit, A. S., de Bruijn, P., Lam, M. H., Chaves, I., et al.
(2015a). Circadian variation in tamoxifen pharmacokinetics in mice and breast
cancer patients. Breast Cancer Res. Treat 152, 119–128. doi: 10.1007/s10549-
015-3452-x
Binkhorst, L., Mathijssen, R. H. J., Jager, A., and van Gelder, T. (2015b).
Individualization of tamoxifen therapy: Much more than just CYP2D6
genotyping. Cancer Treat Rev. 41, 289–299. doi: 10.1016/j.ctrv.2015.
01.002
Binkhorst, L., van Gelder, T., Loos, W. J., de Jongh, F. E., Hamberg, P.,
Moghaddam-Helmantel, I. M., et al. (2012). Effects of CYP induction by
rifampicin on tamoxifen exposure. Clin. Pharmacol. Ther. 92, 62–67. doi: 10.
1038/clpt.2011.372
Borges, S., Desta, Z., Li, L., Skaar, T. C., Ward, B. A., Nguyen, A., et al.
(2006). Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen
metabolism: Implication for optimization of breast cancer treatment. Clin.
Pharmacol. Ther. 80, 61–74. doi: 10.1016/j.clpt.2006.03.013
Braal, C. L., Beijnen, J. H., Koolen, S. L. W., Oomen-de Hoop, E., Steeghs, N., Jager,
A., et al. (2019). Relevance of Endoxifen Concentrations: Absence of Evidence
Is Not Evidence of Absence. J. Clin. Oncol. 37, 1980–1981. doi: 10.1200/jco.19.
00418
Brauch, H., Schroth, W., Goetz, M. P., Mürdter, T. E., Winter, S., Ingle, J. N.,
et al. (2013). Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
J. Clin. Oncol. 31, 176–180. doi: 10.1200/jco.2012.44.6625
Brauch, H., Schroth, W., Mürdter, T., and Schwab, M. (2019). Tamoxifen
Pharmacogenetics and Metabolism: The Same Is Not the Same. J. Clin. Oncol.
37, 1981–1982. doi: 10.1200/jco.19.00507
Buil-Bruna, N., Lopez-Picazo, J.-M., Martin-Algarra, S., and Troconiz, I. F. (2016).
Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of
Pharmacometrics Principles and Applications. Oncologist 21, 220–232. doi:
10.1634/theoncologist.2015-0322
CPIC (2019). CPIC: What is CPIC? [Internet]. Available online at: https://cpicpgx.
org/ (accessed August 18, 2019).
D’Argenio, D. Z. (1981). Optimal sampling times for pharmacokinetic
experiments. J. Pharmacokin. Biopharm. 9, 739–756. doi: 10.1007/bf01070904
Darwich, A. S., Ogungbenro, K., Vinks, A. A., Powell, J. R., Reny, J. L., Marsousi,
N., et al. (2017). Why has model-informed precision dosing not yet become
common clinical reality? lessons from the past and a roadmap for the future.
Clin. Pharmacol. Ther. 101, 646–656. doi: 10.1002/cpt.659
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., et al. (2013).
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping
at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS,
a randomised trial. Lancet 381, 805–816. doi: 10.1016/s0140-6736(12)61963-1
de Graan, A.-J. M., Teunissen, S. F., de Vos, F. Y. F. L., Loos, W. J., van Schaik,
R. H. N., de Jongh, F. E., et al. (2011). Dextromethorphan As a Phenotyping
Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment. J. Clin.
Oncol. 29, 3240–3246. doi: 10.1200/JCO.2010.32.9839
de Vries Schultink, A. H. M., Dorlo, T. P. C., Madlensky, L., Pierce, J. P., Beijnen, J.
H., and Huitema, A. D. R. (2019). Prospective Evaluation of Therapeutic Drug
Monitoring of Endoxifen: Feasibility of Observational and Randomized Trials.
Available online at: www.page-meeting.org/?abstract=9150 (accessed July 15,
2019).
DeCensi, A., Puntoni, M., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L.,
et al. (2019). Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to
Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia.
J. Clin. Oncol. 37, 1629–1637. doi: 10.1200/JCO.18.01779
Dezentjé, V. O., Opdam, F. L., Gelderblom, H., Hartigh den, J., Van der Straaten,
T., Vree, R., et al. (2015). CYP2D6 genotype- and endoxifen-guided tamoxifen
dose escalation increases endoxifen serum concentrations without increasing
side effects. Breast Cancer Res. Treat. 153, 583–590. doi: 10.1007/s10549-015-
3562-5
Fox, P., Balleine, R. L., Lee, C., Gao, B., Balakrishnar, B., Menzies, A. M., et al.
(2016). Dose escalation of tamoxifen in patients with low endoxifen level:
Evidence for therapeutic drug monitoring - The TADE study. Clin. Cancer Res.
22, 3164–3171. doi: 10.1158/1078-0432.CCR-15-1470
Franklin, J. M., Glynn, R. J., Martin, D., and Schneeweiss, S. (2019). Evaluating
the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision
Making. Clin. Pharmacol. Ther. 105, 867–877. doi: 10.1002/cpt.1351
Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., and Leeder, J. S. (2017).
Prediction of CYP2D6 phenotype from genotype across world populations.
Genet. Med. 19, 69–76. doi: 10.1038/gim.2016.80
Gaedigk, A., Simon, S. D., Pearce, R. E., Bradford, L. D., Kennedy, M. J., and Leeder,
J. S. (2008). The CYP2D6 Activity Score: Translating Genotype Information
into a Qualitative Measure of Phenotype. Clin. Pharmacol. Ther. 83, 234–242.
doi: 10.1038/sj.clpt.6100406
Gastonguay, M. R. (2011). Full Covariate Models as an Alternative to Methods
Relying on Statistical Significance for Inferences about Covariate Effects: A Review
of Methodology and 42 Case Studies [Internet]. Available online at: http://www.
page-meeting.org/?abstract=2229 (accessed April 13, 2018).
Gjerde, J., Gandini, S., Guerrieri-Gonzaga, A., Haugan Moi, L. L., Aristarco,
V., Mellgren, G., et al. (2012). Tissue distribution of 4-hydroxy-N-
desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Res. Treat 134,
693–700. doi: 10.1007/s10549-012-2074-9
Frontiers in Pharmacology | www.frontiersin.org 17 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 18
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher,
D. W., et al. (2005). Pharmacogenetics of Tamoxifen Biotransformation Is
Associated With Clinical Outcomes of Efficacy and Hot Flashes. J. Clin. Oncol.
23, 9312–9318. doi: 10.1200/jco.2005.03.3266
Goetz, M. P., Sangkuhl, K., Guchelaar, H. J., Schwab, M., Province, M.,
Whirl-Carrillo, M., et al. (2018). Clinical Pharmacogenetics Implementation
Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin.
Pharmacol. Ther. 103, 770–777. doi: 10.1002/cpt.1007
Goetz, M. P., Suman, V. J., Nakamura, Y., Kiyotani, K., Jordan, V. C., and Ingle,
J. N. (2019). Tamoxifen Metabolism and Breast Cancer Recurrence: A Question
Unanswered by CYPTAM. J. Clin. Oncol. 37, 1982–1983. doi: 10.1200/jco.19.
00504
Goetz, M., Suman, V. J., Reid, J. M., Northfelt, D. W., Mahr, M. A., Ralya,
A. T., et al. (2017). First-in-Human Phase I Study of the Tamoxifen Metabolite
Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
J. Clin. Oncol. 35, 3391–3400. doi: 10.1200/JCO.2017.73.3246
Gong, I. Y., Teft, W. A., Ly, J., Chen, Y. H., Alicke, B., Kim, R. B., et al. (2013).
Determination of clinically therapeutic endoxifen concentrations based on
efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res. Treat
139, 61–69. doi: 10.1007/s10549-013-2530-1
Hansten, P. D. (2018). The Underrated Risks of Tamoxifen Drug Interactions. Eur.
J. Drug. Metab. Pharmacokinet. 43, 495–508. doi: 10.1007/s13318-018-0475-9
Hertz, D. L., Deal, A., Ibrahim, J. G., Walko, C. M., Weck, K. E., Anderson, S.,
et al. (2016). Tamoxifen Dose Escalation in Patients With Diminished CYP2D6
Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Oncologist 21, 795–803. doi: 10.1634/theoncologist.2015-0480
Hoskins, J. M., Carey, L. A., and McLeod, H. L. (2009). CYP2D6 and tamoxifen:
DNA matters in breast cancer. Nat. Rev. Cancer 9:576–586. doi: 10.1038/
nrc2683
InsightRx (2019). [Internet]. Available from: https://insight-rx.com/ (accessed
September 24, 2019).
Irvin, W. J., Walko, C. M., Weck, K. E., Ibrahim, J. G., Chiu, W. K., Dees, E. C.,
et al. (2011). Genotype-Guided Tamoxifen Dosing Increases Active Metabolite
Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study.
J. Clin. Oncol. 29, 3232–3239. doi: 10.1200/JCO.2010.31.4427
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., et al. (2005). CYP2D6
Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant
Breast Cancer Treatment. JNCI 97, 30–39. doi: 10.1093/jnci/dji005
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V.,
et al. (2004). Pharmacological Characterization of 4-hydroxy-N-desmethyl
Tamoxifen, a Novel Active Metabolite of Tamoxifen. Breast Cancer Res. Treat.
85, 151–159. doi: 10.1023/b:brea.0000025406.31193.e8
Karlsson, M. O., and Sheiner, L. B. (1993). The importance of modeling
interoccasion variability in population pharmacokinetic analyses.
J. Pharmacokin. Biopharm. 21, 735–750. doi: 10.1007/bf01113502
Khalaj, Z., Baratieh, Z., Nikpour, P., Schwab, M., Schaeffeler, E., Mokarian, F.,
et al. (2019). Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in
Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased
Concentrations of Tamoxifen and Its Metabolites. Front. Pharmacol. 10:530.
doi: 10.3389/fphar.2019.00530
Kisanga, E. R., Gjerde, J., Guerrieri-gonzaga, A., Pigatto, F., Pesci-feltri, A.,
Robertson, C., et al. (2004). Tamoxifen and Metabolite Concentrations in Serum
and Breast Cancer Tissue during Three Dose Regimens in a Randomized
Preoperative Trial. Clin. Cancer Res. 10, 2336–2343. doi: 10.1158/1078-0432.
ccr-03-0538
Klopp-Schulze, L. (2018). Towards The Individualisation Of Tamoxifen Breast
Cancer Treatment: Leveraging Pharmacometric Approaches. Berlin: Freie
Universitaet Berlin.
Klopp-Schulze, L., Joerger, M., Parra-Guillen, Z., and Kloft, C. (2015). In Silico
Simulation Study: A Comparison Of Two Population Pharmacokinetic Models Of
Tamoxifen And Its Major Metabolite Endoxifen. Available online at: www.page-
meeting.org/?abstract=3447 (accessed July 10, 2019).
Klopp-Schulze, L., Joerger, M., Wicha, S. G., ter Heine, R., Csajka, C., Parra-
Guillen, Z. P., et al. (2018). Exploiting Pharmacokinetic Models of Tamoxifen
and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in
Breast Cancer Patients. Clin. Pharmacokin. 57, 229–242. doi: 10.1007/s40262-
017-0555-z
Laporte-Simitsidis, S., Girard, P., Mismetti, P., Chabaud, S., Decousus, H., and
Boissel, J. (2000). Inter-Study Variability in Population Pharmacokinetic Meta-
Analysis: When and how to Estimate It? J. Pharm. Sci. 89, 155–167. doi:
10.1002/(sici)1520-6017(200002)89:2<155::aid-jps3>3.0.co;2-2
Lash, T. L., Lien, E. A., Sørensen, H. T., and Hamilton-Dutoit, S. (2009). Genotype-
guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 10,
825–833. doi: 10.1016/S1470-2045(09)70030-0
Lim, Y. C., Desta, Z., Flockhart, D. A., and Skaar, T. C. (2005). Endoxifen (4-
hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer
cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother.
Pharmacol. 55, 471–478. doi: 10.1007/s00280-004-0926-7
Madlensky, L., Natarajan, L., Tchu, S., Pu, M., Mortimer, J., Flatt, S. W., et al.
(2011). Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast
cancer outcomes. Clin. Pharmacol. Ther. 89, 718–725. doi: 10.1038/clpt.
2011.32
Martinez, E., Dueñas, D., Ochoa, E., Lopez-barajas, I. B., Ferrer, T., Bandrés, F.,
et al. (2014). Adjusting the dose of tamoxifen in patients with early breast
cancer and CYP2D6 poor metabolizer phenotype. Breast 23, 400–406. doi:
10.1016/j.breast.2014.02.008
Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G.,
Simon, W., et al. (2011). Activity levels of tamoxifen metabolites at the estrogen
receptor and the impact of genetic polymorphisms of phase i and II enzymes
on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 1–10. doi:
10.1038/clpt.2011.27
Neven, P., Jongen, L., Lintermans, A., Van Asten, K., Blomme, C., Lambrechts, D.,
et al. (2018). Tamoxifen metabolism and efficacy in breast cancer: A prospective
multicenter trial. Clin. Cancer Res. 24, 2312–2318. doi: 10.1158/1078-0432.
CCR-17-3028
Poppe, A., Dieudonné, A.-S., Lintermans, A., Laenen, A., Blomme, C., Lambrechts,
D., et al. (2016). Abstract P3-07-46: CYPTAM-BRUT 3: Endometrial thickness
cannot be used as a marker for tamoxifen metabolization in postmenopausal
breast cancer patients. Cancer Res. 76, 1538–7445.
Ratain, M. J., Nakamura, Y., and Cox, N. J. (2013). CYP2D6 Genotype and
Tamoxifen Activity: Understanding Interstudy Variability in Methodological
Quality. Clin. Pharmacol. Ther. 94, 185–187. doi: 10.1038/clpt.2013.66
Ravva, P., Gastonguay, M. R., Tensfeldt, T. G., and Faessel, H. M. (2009).
Population pharmacokinetic analysis of varenicline in adult smokers. Br. J. Clin.
Pharmacol. 68, 669–681. doi: 10.1111/j.1365-2125.2009.03520.x
Regan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R.,
et al. (2012). CYP2D6 Genotype and Tamoxifen Response in Postmenopausal
Women with Endocrine-Responsive Breast Cancer: The Breast International
Group 1-98 Trial. JNCI J. Natl. Cancer Inst. 104, 441–451. doi: 10.1093/jnci/
djs125
Ribba, B., Holford, N. H., Magni, P., Trocóniz, I., Gueorguieva, I., Girard, P.,
et al. (2014). A review of mixed-effects models of tumor growth and effects
of anticancer drug treatment used in population analysis. CPT Pharmacometr.
Syst. Pharmacol. 3:e113. doi: 10.1038/psp.2014.12
Saladores, P., Mürdter, T., Eccles, D., Chowbay, B., Zgheib, N. K., Winter, S., et al.
(2015). Tamoxifen metabolism predicts drug concentrations and outcome in
premenopausal patients with early breast cancer. Pharmacogenom. J. 15, 84–94.
doi: 10.1038/tpj.2014.34
Sanchez-Spitman, A., Dezentjé, V., Swen, J., Moes, D. J. A. R., Böhringer, S.,
Batman, E., et al. (2019). Tamoxifen Pharmacogenetics and Metabolism: Results
From the Prospective CYPTAM Study. J. Clin. Oncol. 37, 636–646. doi: 10.1200/
JCO.18.00307
Schroth, S., Mürdter, T., Schaeffeler, E., Eccles, D., Eccles, B., Chowbay, B., et al.
(2017). Improved Prediction of Endoxifen Metaboslism by CYP2D6 Genotype
in Breast Cancer Patients Treated with Tamoxifen. Front. Pharmacol. 8:582.
doi: 10.3389/fphar.2017.00582
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M.,
et al. (2007). Breast cancer treatment outcome with adjuvant tamoxifen relative
to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25, 5187–5193.
doi: 10.1200/jco.2007.12.2705
Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava,
P., et al. (2003). Active Tamoxifen Metabolite Plasma Concentrations After
Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor
Paroxetine. JNCI 95, 1758–1764. doi: 10.1093/jnci/djg108
Frontiers in Pharmacology | www.frontiersin.org 18 March 2020 | Volume 11 | Article 283
fphar-11-00283 March 28, 2020 Time: 18:59 # 19
Klopp-Schulze et al. Model-Informed Dosing of Tamoxifen
TAMENDOX. (2020). Genotype and Phenotype Guided Supplementation of
TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
(TAMENDOX) [Internet]. Available online at: https://clinicaltrials.gov/ct2/
show/study/NCT03931928?term=TAMENDOX&draw=2&rank=1 (accessed
January 14, 2020).
Ter Heine, R., Binkhorst, L., De Graan, A. J. M., De Bruijn, P., Beijnen, J. H.,
Mathijssen, R. H. J., et al. (2014). Population pharmacokinetic modelling
to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the
pharmacokinetics of tamoxifen and endoxifen. Br. J. Clin. Pharmacol. 78,
572–586. doi: 10.1111/bcp.12388
Tunblad, K., Lindbom, L., McFadyen, L., Jonsson, E. N., Marshall, S., and Karlsson,
M. O. (2008). The use of clinical irrelevance criteria in covariate model
building with application to dofetilide pharmacokinetic data. J. Pharmacokinet.
Pharmacodyn. 35, 503–526. doi: 10.1007/s10928-008-9099-z
Wallin, J. E., Friberg, L. E., and Karlsson, M. O. (2010). Model-Based Neutrophil-
Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome
with Different Types and Amounts of Information. Basic Clin. Pharmacol.
Toxicol. 106, 234–242. doi: 10.1111/j.1742-7843.2009.00520.x
Welzen, M. E. B., Dezentjé, V. O., Schaik, R. H. N., Van Colbers, A. P. H.,
Guchelaar, H., Erp, N. P., et al. (2015). The Effect of Tamoxifen Dose Increment
in Patients With Impaired CYP2D6 Activity. Ther. Drug. Monit. 37, 501–507.
doi: 10.1097/FTD.0000000000000195
Wicha, S. G., Kees, M. G., Solms, A., Minichmayr, I. K., Kratzer, A., and Kloft,
C. (2015). TDMx: A novel web-based open-access support tool for optimising
antimicrobial dosing regimens in clinical routine. Int. J. Antimicrob. Agents 45,
442–444. doi: 10.1016/j.ijantimicag.2014.12.010
Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M., and Gelmon, K. A. (2010).
Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11,
174–183. doi: 10.1016/s1470-2045(09)70262-1
Zembutsu, H., Nakamura, S., Akashi-Tanaka, S., Kuwayama, T., Watanabe, C.,
Takamaru, T., et al. (2017). Significant Effect of Polymorphisms in CYP2D6 on
Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter
Study. Clin. Cancer Res. 23, 2019–2026. doi: 10.1158/1078-0432.CCR-16-
1779
Conflict of Interest: LK-S is currently employed by Merck Healthcare KGaA,
Germany. CK reports grants from an industry consortium (AbbVie Deutschland
GmbH & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG, Grünenthal
GmbH, F. Hoffmann-La Roche Ltd., Merck KGaA and Sanofi) for the PharMetrX
program and the Innovative Medicines Initiative-Joint Undertaking (‘DDMoRe’).
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Klopp-Schulze, Mueller-Schoell, Neven, Koolen, Mathijssen,
Joerger and Kloft. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 19 March 2020 | Volume 11 | Article 283
